SEC Form 3 · accession 0001209191-19-003289
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter P. Pfreundschuh
Officer — CFO
Period of report
Jan 1, 2019
Accepted (ET)
Jan 10, 2019 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | holding | — | — | — | 1,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $42.23 | holding | — | — | — | — | Aug 20, 2028 | Ordinary Shares | 50,000 | — | D |
| Restricted Stock UnitF3,F2 | — | holding | — | — | — | — | — | Ordinary Shares | 12,500 | — | D |
Explanation of responses
- F133.33% of the shares underlying the stock option will vest on August 20, 2019 and 8.33% of the remaining shares will vest in equal quarterly installments thereafter.
- F233.33% of the restricted stock units ("RSUs") will vest on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.
- F3Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney